These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 2720661

  • 1. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
    Kees UR, Ford J, Dawson VM, Piall E, Aherne GW.
    Cancer Res; 1989 Jun 01; 49(11):3015-9. PubMed ID: 2720661
    [Abstract] [Full Text] [Related]

  • 2. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K, Nayak R, Grant S.
    Cancer Res; 1984 Nov 01; 44(11):5029-37. PubMed ID: 6091869
    [Abstract] [Full Text] [Related]

  • 3. Resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment childhood lymphoblastic leukemia: isolation of a drug resistant and a sensitive cell line.
    Kees UR.
    Cancer Res; 1987 Jun 15; 47(12):3088-91. PubMed ID: 3472651
    [Abstract] [Full Text] [Related]

  • 4. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
    Riva CM, Rustum YM.
    Cancer Res; 1985 Dec 15; 45(12 Pt 1):6244-9. PubMed ID: 2998596
    [Abstract] [Full Text] [Related]

  • 5. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
    Abe I, Saito S, Hori K, Suzuki M, Sato H.
    Cancer Res; 1982 Jul 15; 42(7):2846-51. PubMed ID: 7083175
    [Abstract] [Full Text] [Related]

  • 6. Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67).
    Grant S, Freemerman AJ, Birrer MJ, Martin HA, Turner AJ, Szabo E, Chelliah J, Jarvis WD.
    Cell Growth Differ; 1996 May 15; 7(5):603-13. PubMed ID: 8732670
    [Abstract] [Full Text] [Related]

  • 7. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ.
    Cancer Res; 1987 Jun 01; 47(11):3005-11. PubMed ID: 3471322
    [Abstract] [Full Text] [Related]

  • 8. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
    Chandrasekaran B, Capizzi RL, Kute TE, Morgan T, Dimling J.
    Cancer Res; 1989 Jun 15; 49(12):3259-66. PubMed ID: 2720678
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Substrate-specific deoxycytidine kinase deficiency in 1-beta-D-arabinofuranosylcytosine-resistant leukemic cells.
    Richel DJ, Colly LP, Arkesteijn GJ, Arentsen-Honders MW, Kerster MG, ter Riet PM, Willemze R.
    Cancer Res; 1990 Oct 15; 50(20):6515-9. PubMed ID: 2208110
    [Abstract] [Full Text] [Related]

  • 12. Formation of cytosine arabinoside-5'-triphosphate in cultured human leukemic cell lines correlates with nucleoside transport capacity.
    Tanaka M, Yoshida S.
    Jpn J Cancer Res; 1987 Aug 15; 78(8):851-7. PubMed ID: 3115933
    [Abstract] [Full Text] [Related]

  • 13. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI, Biener R, Krailo M, Finklestein J, Ettinger L, Willoughby M, Siegel SE, Holcenberg JS.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [Abstract] [Full Text] [Related]

  • 14. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Hug V, Keating MJ, Chubb S.
    Cancer Res; 1980 Mar 15; 40(3):588-91. PubMed ID: 6937239
    [Abstract] [Full Text] [Related]

  • 15. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.
    Bergman AM, Kuiper CM, Voorn DA, Comijn EM, Myhren F, Sandvold ML, Hendriks HR, Peters GJ.
    Biochem Pharmacol; 2004 Feb 01; 67(3):503-11. PubMed ID: 15037202
    [Abstract] [Full Text] [Related]

  • 16. Pharmacology of intracellular cytosine-arabinoside-5'-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes.
    Koehl U, Hollatz G, Rohrbach E, Visschedyk K, Cinatl J, Kornhuber B, Kreuter J, Mutschler E, Schwabe D.
    Cancer Chemother Pharmacol; 2007 Sep 01; 60(4):467-77. PubMed ID: 17171362
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.
    Grant S, Turner A, Nelms P, Yanovich S.
    Leukemia; 1995 May 01; 9(5):808-14. PubMed ID: 7769843
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Regulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in human leukemia cells by deoxycytidine 5'-triphosphate.
    Liliemark JO, Plunkett W.
    Cancer Res; 1986 Mar 01; 46(3):1079-83. PubMed ID: 3484676
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.